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Background: HIV-infected pregnant women are particularly more susceptible to the deleterious effects of malaria
infection particularly anaemia. In order to prevent opportunistic infections and malaria, a policy of daily co-trimoxazole
prophylaxis without the standard Suphadoxine-Pyrimethamine intermittent preventive treatment (SP-IPT) was introduced
to all HIV infected pregnant women in the year 2011. However, there is limited information about the effectiveness of this
policy.
Methods: This was a cross sectional study conducted among HIV-infected pregnant women receiving co-trimoxazole
prophylaxis in eight public health facilities in Kinondoni Municipality from February to April 2013. Blood was tested for
malaria infection and anaemia (haemoglobin <11 g/dl). Data were collected on the adherence to co-trimoxazole
prophylaxis and other risk factors for malaria infection and anaemia. Pearson chi-square test, Fischer’s exact test and
multivariate logistic regression were used in the statistical analysis.
Results: This study enrolled 420 HIV infected pregnant women. The prevalence of malaria infection was 4.5%, while that
of anaemia was 54%. The proportion of subjects with poor adherence to co-trimoxazole was 50.5%. As compared to HIV
infected pregnant women with good adherence to co-trimoxazole prophylaxis, the poor adherents were more likely
to have a malaria infection (Adjusted Odds Ratio, AOR = 6.81, 95% CI = 1.35-34.43, P = 0.02) or anaemia (AOR = 1.75, 95%
CI = 1.03-2.98, P = 0.039). Other risk factors associated with anaemia were advanced WHO clinical stages, current malaria
infection and history of episodes of malaria illness during the index pregnancy.
Conclusion: The prevalence of malaria was low; however, a significant proportion of subjects had anaemia. Good
adherence to co-trimoxazole prophylaxis was associated with reduction of both malaria infection and anaemia among
HIV infected pregnant women.
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Combined malaria and HIV infection during pregnancy in-
creases the susceptibility of the pregnant women to the
negative effects of malaria suggesting a synergistic inter-
action between HIV infection and malaria [1,2]. HIV-
infected pregnant women have significant alterations in
immunity to malaria, which render them more vulnerable* Correspondence: minziobejayesu@gmail.com
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article, unless otherwise stated.to the negative effects related to malaria infection [3,4].
This population experiences consistently more peripheral
and placental malaria, higher parasite densities, more febrile
illnesses, severe anaemia, and adverse birth outcomes than
HIV uninfected women regardless of the parity [2].
WHO has recommended a daily dose of co-trimoxazole
among HIV-infected pregnant women during the whole
pregnancy period in order to prevent opportunistic infec-
tions and malaria [5]. Concurrent administration of SP and
co-trimoxazole is not advised to avoid adverse reactions [5].
Tanzania had adopted this policy since the year 2011 [6].tral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
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iveness of daily co-trimoxazole for preventing malaria and
its deleterious effects particularly anaemia among HIV in-
fected pregnant women.
This study was carried out in a malaria endemic area
characterized by malaria transmission throughout the
year [7]. In this area, peripheral parasitaemia among
pregnant women can be absent or below the detection
limit of the microscopic method [8,9]. To overcome this
challenge, we used selected malaria rapid diagnostic tests
(MRDT) targeting antigens called histidine rich protein
2 (HRP-2). These antigens are released by red blood cells
infected by the malaria parasites; they can be detected in
the peripheral circulation even when the parasites are
sequestered within the placenta [9,10].
This cross sectional study reports the prevalence of
malaria, anaemia and the associated risk factors among
HIV infected pregnant women receiving co-trimoxazole
prophylaxis in one district in Tanzania.
Methods
Study design and study area
The design of the study was a cross sectional. It was
conducted between February and April 2013 in eight
public health facilities in Kinondoni municipality, Dar Es
Salaam. Kinondoni has a hot and humid tropical climate
with two rainfall seasons: an intense one observed from
the month of March to May, and a mild one in Novem-
ber and December. The average temperature ranges
from a minimum of 18.1°C to a maximum of 32.1°C.
The average annual rainfall is 1,115 mm. A theoretical
model based on data for rainfall and temperature char-
acterizes Kinondoni as an area with stable malaria trans-
mission (holoendemic), with transmission occurring
during the entire year [7]. Malaria is the leading cause of
both the outpatient visits and inpatient admissions [11].
Study population
The targeted subjects were HIV infected pregnant
women receiving co-trimoxazole prophylaxis for more
than four weeks. Sample size for this study was calcu-
lated using the formula for cross-sectional study based
on the study done in Uganda [12]. In that study; thse
prevalence of malaria infection among HIV infected
pregnant women using co-trimoxazole prophylaxis (x)




n =Minimum sample size, z = point on standard nor-
mal distribution curve corresponding to significance
level of 5% (its value is 1.96), x = previous prevalence of
malaria infection among HIV infected pregnant womenreceiving co-trimoxazole prophylaxis (19%), ε =margin
of error on x (set at 4%). A total of 420 consented sub-
jects on different trimesters and varied gravidities were
enrolled into the study. Pregnant women with sickle cell
disease, vaginal bleeding and severe medical conditions
were excluded from the study.
Sampling procedure
Kinondoni municipality has a total of 33 public health facil-
ities; among them two are hospitals, one is a health centre
and thirty are dispensaries. Cluster sampling was used for
selection of health facilities to be included in the study. The
health facilities were divided into three clusters, namely
hospitals, health centre and dispensaries. The two hospitals
and the health centre were included in the study. Five out
of the thirty dispensaries were selected using simple ran-
dom sampling without replacement technique. Each name
of the 30 dispensaries was written on a small piece of paper,
and then the paper was folded to ‘a ball like’ figure and put
in a mug. The mug was thoroughly shaken and five ‘paper
balls’ were randomly picked to select the five dispensaries.
Two hospitals involved in the study were Mwananyamala
and Sinza. A Health Centre involved was Magomeni; and
the five dispensaries were Kambangwa, Tandale, Mburahati,
Kimara and Mbezi.
Due to the limited number of HIV infected pregnant
women, all the subjects in the selected clusters who met
the inclusion criteria were enrolled in the study.
Data collection methods
A structured interview schedule was used to obtain infor-
mation on various characteristics of the subjects and sup-
plemented by information from patients' files. These
include age, weight, height, gravidity, marital status, educa-
tion level, employment status, WHO clinical stage, use of
insecticide treated nets (ITN), history of episodes of malaria
illness, use of iron supplements, use of deworming drugs,
anti-retroviral treatment category (prophylaxis or lifelong),
duration of zidovudine use. The subjects were then tested
for malaria and anaemia. The blood sample was collected
for CD4 assay.
Adherence to co-trimoxazole prophylaxis
Adherence to co-trimoxazole prophylaxis was measured
by using an interview schedule adapted from Morisky
medication adherence scale (Table 1) [13,14].
Haemoglobin measurement
Haemoglobin was measured by HemoCue Hb 201 + ® ma-
chine manufactured by HemoCue AB Ängelholm, Sweden.
The tip of the middle finger was cleaned by alcohol swab;
then a blood sample was obtained by finger pricking pro-
cedure. The Haemocue 201 + ® cuvette was filled with
blood, excess blood was cleaned from the cuvette and air
Table 1 A scale used to determine the adherence level for co-trimoxazole prophylaxis among HIV infected pregnant
women
No. Questions Yes No
i Do you sometimes forget to take your co-trimoxazole tablets? 0 1
ii People sometimes miss taking their medicines for reasons other than forgetting. Thinking over the past 2 weeks, were there any days
when you did not take your co-trimoxazole tablets?
0 1
iii Have you ever cut back or stopped taking co-trimoxazole without telling your doctor because you felt worse when you took it? 0 1
iv When you travel or leave home, do you sometimes forget to bring along co-trimoxazole tablets? 0 1
v Did you take your co-trimoxazole tablets yesterday? 1 0
vi Taking medicines every day is a real inconvenient for some people. Do you ever feel hassled about sticking to your treatment plan? 0 1
vii How often do you have difficulty remembering to take co-trimoxazole tablets?
 Never/Rarely = 1
 Once in a while = 0.75
 Sometimes = 0.5
 Usually = 0.25
 All the time = 0
TOTAL SCORE
Note: The total score of >6 was interpreted as Good adherence, 4 to 5.9 as Average Adherence and <4 as Poor Adherence.
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vice tray and the holder was pushed gently into the pho-
tometer. The results were recorded from the digital display.
Malaria testing
Malaria was tested by using SD BIOLINE Malaria Ag P.
f/Pan® MRDT manufactured by Standard Diagnostics,
Inc, Korea. The blood sample was collected by finger
prick method after the tip of the middle finger was
cleaned by alcohol swab. The test device was placed on
a clean, flat surface. About 5 μl of whole blood were
added into the ‘sample well’ of respective test devices
using a micropipette supplied with the test device. Four
drops of assay diluent were added into the ‘sample dilu-
ent well’. All the test results were recorded within
30 minutes.
CD-4 count
The CD-4 Count was done at Mwananyamala Hospital
by BD FACS Count® Machine (BD Biosciences USA).
About 4 ml of whole blood (4 ml) was collected in
EDTA collection tubes by standard venipuncture pro-
cedure. The collected samples were kept at room
temperature (18-25°C) and then transported in a special
container. All samples were processed within 30 hours
from the time of collection.
Management of patients
Pregnant women who were diagnosed with malaria or
anaemia during the study were managed as per the
Tanzania’s Standard Treatment Guidelines through the
respective health facilities.Data analysis
Data were double-entered, cleaned and analysed using
computer software called IBM SPSS Statistics 20 (IBM
Corp.). Dependent variables were malaria infection and
anaemia. While the independent variables were the
levels of adherence to co–trimoxazole prophylaxis.
Other independent variables were socio-demographic
factors, WHO clinical stages, CD-4 count bands, gra-
vidity, pregnancy age (trimesters), sleeping under in-
secticide treated bed nets (ITN), history of episodes of
malaria illness, use of iron supplements, the use of de-
worming agent and duration of AZT use (categorized
as <3 months, 3 to <6 months and ≥6 months).
Classification of anaemia was based on the recommenda-
tion by WHO [15]; normal (Hb ≥11 g/dl), mild anaemia
(Hb = 10-10.9 g/dl), moderate anaemia (Hb = 7-9.9 g/dl)
and severe anaemia (Hb < 7 g/dl). CD4 count was catego-
rized according to the four bands of HIV related immuno-
deficiency proposed by WHO [16]. These include: no
significant immunodeficiency (≥500 cells/μL), mild im-
munodeficiency (350–499 cells/μL), advanced immunodefi-
ciency (200–349 cells/μL) and severe immunodeficiency
(<200 μL).
Pearson Chi-square Test and Fischer’s Exact Test were
used in the univariate analysis between the dependent
and independent variables where applicable. Independ-
ent variables which showed a statistical significant dif-
ference with the outcome variable by univariate analysis
were subjected to multivariate logistic regression to
determine the predictors of the outcome. The P-value
of < 0.05 was considered significant to provide evidence
of significant difference or association.
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Ethical approval for the study was given by the Ethical
Committee of the Muhimbili University of Health and Al-
lied sciences (MUHAS). Permission from Kinondoni Muni-
cipal Council to conduct the study in the health facilities
was granted. Information about the study was delivered to
the patients and a written consent was obtained before the
study was conducted. Confidentiality was ensured to all in-
dividuals who participated in the study.
Results
Characteristics of the study population
From February to April 2013, a total of 420 HIV infected
pregnant women in various trimesters were enrolled into
the study. The mean ± SD age of the subjects was 28 ±
5.2 years. Table 2 summarizes sociodemographic charac-
teristics of the HIV infected pregnant women who were
enrolled in the study.
Prevalence of malaria
The study revealed a prevalence of malaria of 4.5% (19/
420). Table 3 shows the prevalence of malaria, according to
selected risk factors. A pattern was seen towards the in-
crease in the prevalence of malaria infection as the levels of
adherence to co-trimoxazole prophylaxis decreased from
good to poor. Pregnant women with poor adherence to co-
trimoxazole prophylaxis were 6.8 times more likely to have
a malaria infection as compared to those with good adher-
ence (AOR= 6.81, 95% CI =1.35-34.43 and P = 0.02). TheTable 2 Socio-demographic characteristics of HIV infected
pregnant women who were enrolled in the study
(N = 420)

















Not employed 109 25.95prevalence of malaria was statistically similar in all gravid-
ities (P = 0.563).
Prevalence of anaemia
The prevalence of any anaemia (Hb <11 g/dl) was found
to be 54% (227/420); while that of mild-to-moderate an-
aemia and severe anaemia were 49.3% (207/420) and 5%
(21/420) respectively. The overall mean ± SD haemoglo-
bin concentration was 10.3 ± 1.5 g/dl.
Table 4 shows the prevalence of anaemia according to
various selected risk factors among HIV infected preg-
nant women. The prevalence of anaemia increased as
the levels of adherence to co-trimoxazole prophylaxis
decreased from good to poor. Subjects who had poor ad-
herence were 1.8 times more likely to have anaemia as
compared to those with good adherence (AOR = 1.75,
95% CI = 1.03-2.98 and P = 0.041).
The prevalence of anaemia among subjects with malaria
infection was 94.7% (18/19) as compared to 52.1% (209/
401) among malaria negative subjects. Malaria infected sub-
jects were 10.4 times more likely to have anaemia as com-
pared to those who had a negative malaria test (AOR = 10.
36, 95% CI = 1. 33–80.8, P = 0.026). Likewise, subjects who
had at least one episode of malaria illness during the
current pregnancy were 1.8 times more likely to have an-
aemia as compared with those without a history (AOR =
1.75 95% CI = 1.01-3.03, P = 0.048).
The prevalence of anaemia increased as the HIV/AIDS
advanced from lower to higher WHO clinical stages (i.e.
from stage I to IV). Pregnant women who were on
WHO clinical stage III or IV were 2.7 times more likely
to have anaemia as compared to those on WHO clinical
stage I (AOR = 2.65, 95% CI = 1.18-5.95 and P = 0.018).
Discussion
This study shows that the prevalence of malaria infection
was 4.5% among HIV infected pregnant women receiving
co-trimoxazole prophylaxis. A similar low prevalence was
obtained in a previous study that was conducted in Malawi
by Kapito-Tembo et al. [17]. In that study, the prevalence
of malaria among HIV infected pregnant women who were
receiving co-trimoxazole prophylaxis was 2.7% and 5.5% by
blood smear and real time PCR method respectively. The
Malawian study differs from the present study in the
method of malaria diagnosis. Real-time PCR targets parasite
DNA and has a higher sensitivity than the MRDT; while
the blood smear method by microscopy is less sensitive
compared to MRDT [9,10,18].
The prevalence of malaria infection increased as the level
of adherence to co-trimoxazole decreased from good to
poor. Pregnant women with poor adherence were almost
seven times more likely to have a malaria infection as com-
pared to those with good adherence. We could not find any
previous study that investigated the association between the
Table 3 Prevalence of malaria according to selected risk factors among HIV infected pregnant women receiving
co-trimoxazole (N = 420)
Characteristics N Malaria prevalence n (%) P-value AOR 95% CI P-value
WHO clinical stage
Stage I 338 12 (3.6) 1
Stage II 43 2 (4.7) 0.851 0.171-4.226 0.844
Stage III-IV 39 5 (12.8) 0.031a 2.305 0.699-7.597 0.170
CD4 count (cells/μL)*
≥500 104 4 (3.8) -
350-499 85 3 (3.5) -
200-349 96 8 (8.3) −
<200 59 4 (6.8) 0.417a -
Pregnancy trimester
1st trimester 20 1 (5) -
2nd trimester 206 9 (4.4) -
3rd trimester 194 9 (4.6) 0.986a -
Gravidity
Primigravidae 139 6 (4.3) -
Secundigravidae 148 5 (3.4) -
Multigravidae 133 8 (6) 0.563a -
Adherence to co-trimoxazole
Good 208 2 (1) 1
Average 80 4 (5) 3.578 0.611-20.955 0.157
Poor 132 13 (9.8) 0.001a 6.806 1.346-34.429 0.02
ITN use
Yes 380 15 (3.9) -
No 40 4 (10) 0.096b -
ART use category
Prophylaxis 288 11 (3.8) -
Life long 132 8 (6.1) 0.305a -
aCalculated by Pearson Chi Square, bCalculated by Fischer’s Exact Test, *Results of CD4 count were available for only 344 subjects out of 420 (81.9%).
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prophylaxis among similar subjects. An explanation for the
pattern seen in our study could be the fact that the good
adherents had higher exposure to co-trimoxazole and
therefore were more protected as compared with the poor
adherents.
Sleeping under insecticide treated nets (ITN) by the
subjects could as well have contributed to the low preva-
lence of malaria in this study group as it was reported in
previous studies [19-21]. ITN are freely available to all
pregnant women through a voucher system at antenatal
clinics [21]. The prevalence of malaria among the sub-
jects who reported to sleep under an ITN was low at
3.9% as compared to those who did not sleep under an
ITN which was 10%. The use of ITN control malaria
transmission by creating a barrier between the mosqui-
toes and people sleeping under them [20,21]. Moreover,the insecticides that are used for treating bed nets kill or
repel the mosquitoes; consequently, the numbers of
mosquitoes that enter the household and attempt to feed
on people inside are reduced as well as shortening their
length of life [20,21]. Nevertheless, the finding was sta-
tistically not significant. This is consistent with the study
by West et al. [22], in which other factors excluding ITN
were significantly associated with malaria infection in a
community with high and equitable distribution of ITN.
In consistent with previous studies [2,12,17,23], mal-
aria infection was distributed to all the gravidities. The
explanation for this outcome is that HIV affects the im-
mune memory mechanism which is responsible for the
parity-dependent acquisition of antimalarial immunity in
pregnancy and therefore predisposes the secundigravidae
and multigravidae to a similar risk of malaria infection
as the primigravidae [2].
Table 4 Prevalence of anaemia according to selected risk factors among HIV infected pregnant women receiving
co-trimoxazole prophylaxis (N = 420)
Univariate analysis Multivariate analysis
Characteristics n Prevalence of anaemia n (%) P-value AOR 95% CI P-value
Malaria infection
Yes 19 18 (94.7) 10.363 1.329-80.798 0.026
No (reference) 401 209 (52.1) 0.0001a 1
History of malaria illness
Yes 107 76 (71) 1.746 1.005-3.033 0.048
No (reference) 313 151 (48.2) 0.0001a 1
WHO clinical stage
Stage I (reference) 338 165 (48.8) 1
Stage II 43 32 (74.4) 3.076 1.458-6.491 0.003
Stage III-IV 37 30 (76.9) 0.0001a 2.653 1.184-5.945 0.018
CD4 count (cells/μL)*
≥500 104 48 (46.2) -
350-499 85 45 (52.9) -
200-349 96 62 (64.6) −
<200 59 42 (71.2) 0.005a -
Pregnancy trimester
1st trimester 20 9 (45) -
2nd trimester 206 107 (51.9) -
3rd trimester 194 111 (57.2) 0.404a -
Gravidity
Primigravidae 139 72 (51.8) -
Secundigravidae 148 83 (56.1) -
Multigravidae 133 72 (54.1) 0.767a -
ITN use
Yes 380 201 (52.9) -
No 40 26 (65) 0.144a -
ART category
ARV Prophylaxis 288 146 (50.7) -
Life-long ART 132 81 (61.4) 0.142a -
Duration of AZT use (months)
<3 162 93 (57.4) -
3-5.9 168 92 (54.8) −
≥6 90 42 (46.7) 0.253a -
Iron supplements
Yes 338 185 (54.7) -
No 82 42 (51.2) 0.567a -
Use of de-worming drug
Yes 327 171 (52.3) -
No 93 56 (60.2) 0.176a -
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Table 4 Prevalence of anaemia according to selected risk factors among HIV infected pregnant women receiving
co-trimoxazole prophylaxis (N = 420) (Continued)
Adherence to co-trimoxazole
Good (reference) 208 92 (44.2) 1
Average 80 47 (58.8) 1.478 0.848-2.578 0.168
Poor 132 88(66.7) 0.0001a 1.752 1.03-2.979 0.039
aCalculated by Pearson Chi Square, *Results of CD4 Count were available for only 344 subjects out of 420 (81.9%).
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which are used to monitor progression of HIV/AIDS
[5,24]. This study could not find an association between
the prevalence of malaria infection and low CD4 count
or advanced WHO clinical stages; which are known to
increase the vulnerability to malaria infection [2]. This
could be explained by the impact of malaria control in-
terventions; particularly the use of co-trimoxazole
prophylaxis and sleeping under an ITN among HIV in-
fected pregnant women. Kapito-Tembo et al. [17] re-
ported similar findings in Malawi whereby HIV infected
pregnant women at all bands of CD4 counts (i.e. <200,
200–499 and ≥500 cells/μL) had a similar risk of malaria
infection.
The present study showed that the prevalence of an-
aemia among HIV infected pregnant women receiving
co-trimoxazole prophylaxis was 54%. Previous studies
that were conducted in the Dar Es Salaam city reported
higher prevalence compared to the present study.
Finkelstein et al. [25] reported a prevalence of 83% in 1997,
while Mehta et al. [26] reported a prevalence of 73% in
2003. Other studies that were conducted in different coun-
tries within Sub-Saharan Africa have reported varied values
of the prevalence of anaemia among similar subjects
[2,17,27,28]. In Malawi; Kapito-Tembo et al. [17] reported a
prevalence of 35.6%; while Nkhoma et al. [28] reported a
prevalence of 27.4%. In Nigeria, a prevalence of 83.8% was
reported by Uneke et al. [27]. The reasons for these varia-
tions are not clear, but may be connected to the complexity
and the multifactorial aetiology of anaemia among HIV in-
fected pregnant women in sub-Saharan Africa, including
HIV/AIDS itself, malaria, protein and micronutrient defi-
ciency and endemic diseases like hookworm and schisto-
somiasis [25,27].
Good adherence to co-trimoxazole was associated with
reduced prevalence of anaemia. A pattern was seen to-
wards the increase in the prevalence of maternal an-
aemia as the levels of adherence to co-trimoxazole
prophylaxis decreased from good to poor. Poor Adher-
ents were almost 1.8 times more likely to have anaemia
as compared with good adherents. This could be due to
the fact that, well adherent subjects had more exposure
to the co-trimoxazole drug and therefore they were
more protected from malaria infection and its sequelae
particularly anaemia as compared to the poor adherentone. Walker et al. [29], had previously reported the ben-
efits of co-trimoxazole in reducing morbidities among
the HIV infected population; this could similarly explain
the reduction in anaemia among good adherents.
In consistent with a previous study by Finkelstein et al.
[25], advanced HIV/AIDS clinical stages (clinical stage
III or IV) or CD4 Count of < 200 had a strong associ-
ation with anaemia. The subjects who were on WHO
clinical stage III or IV were 3 times more likely to have
anaemia as compared with those in the WHO clinical
stage I. Similarly, the prevalence of anaemia increased as
the CD4 Count decreases among the subjects. This pat-
tern could be explained by the fact that subjects with ad-
vanced clinical stages or a low CD4 count had poor
immunity against malaria and other infections were
therefore more vulnerable to becoming anaemic [3,4].
Furthermore, advanced HIV/AIDS is associated with
local diseases along the gastrointestinal tract, which
could eventually result in poor absorption of nutrients
necessary for the formation of haemoglobin [26].
Low CD-4 count and advanced HIV/AIDS stages re-
flect the chronicity (prolonged existence) of the disease;
therefore another cause of anaemia could also be the
state of chronic illnesses [30,31]. The immune response
mounted against such infections is required for patho-
gen clearance, but its persistence can cause collateral
damage to the host with the occurrence of anaemia as
the major pathology [30]. The inflammation triggers the
release of chemicals e.g. hepcidin, that signal the iron
regulation mechanism to adopt a defensive mode. This
type of anaemia is usually characterized by an imbalance
between erythro-phagocytosis and erythropoiesis [30,31].
Similar to previous studies [2,27,28], dually infected
(HIV plus malaria infection) pregnant women were at
considerably greater risk of anaemia as compared with
those with HIV infection alone. HIV infected pregnant
women who had positive malaria test were ten times
more likely to have anaemia as compared with those
who had the negative malaria test. Both HIV (particu-
larly with advanced immunosuppression) and malaria in-
fection are individually known causes of anaemia [2].
Anaemia associated with malaria is caused by hemolysis
of the red blood cells and hypersplenism, a condition
characterized by the exaggeration of inhibitory or de-
structive function of the spleen [15].
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illness during the current pregnancy were nearly two times
more likely to have anaemia as compared with those with-
out a history. In consistent with this study, Nkhoma et al.
[28] reported a significant association between the number
of previous malaria episodes and maternal anaemia; having
two or more episodes were associated with increased risk
of anaemia. The reason could be the fact that both HIV
(particularly with advanced immunosuppression) and mal-
aria infection are individually known causes of anaemia [2].
In disagreement with previous knowledge [32-34]; the
present study could not find a significant association be-
tween anaemia and zidovudine use. This could be due to
the positive role of the antiretroviral drugs and co-
trimoxazole in controlling the HIV infection and other
morbidities and subsequently outweighed the anaemia in-
ducing effect of zidovudine. Furthermore, the multi-
aetiologies of anaemia in HIV infected pregnant women in
Sub-Saharan Africa [25] e.g. HIV infection itself, malaria in-
fection, nutrients deficiency and worm infestations could
be the reason for the high prevalence in both groups and
consequently lack of significant difference. Sinha et al. [35]
reported similar findings in a study conducted in India. In
that study [35], pregnant women who used zidovudine
were surprisingly 70% less likely to be anaemic compared
with women not receiving zidovudine.
Similar to a study by Finkelstein et al. [25], anaemia
prevalence was higher in both the subjects who used iron
supplements and those who did not; likewise to the use of
de-worming agents. Lack of significant difference between
the groups could be explained by the complexity and multi-
factorial aetiology of anaemia apart from the iron deficiency
or worm infestation among HIV infected pregnant women
in Sub-Saharan Africa [25,30,31].
Our study had some limitations. We attempted to control
the confounders by the multivariate logistic regression;
nonetheless, there were potential residual confounding ef-
fects from the unmeasured factors like the presence of
other infections or pathological conditions. Secondly, be-
cause of the cross sectional design of this study, we had
only one point of measurement of both the outcomes and
exposure; this made it difficult to make a causal inference
from the findings. Thirdly, our results may have potentially
been affected by information bias because measurement of
adherence to co-trimoxazole prophylaxis was done by a
self-reported method and no drug levels in the blood were
measured. Likewise, the use of iron supplements, de-
worming drugs and sleeping under an ITN were self-
reported. However, antenatal records were used to verify
prescriptions of medications.
Conclusions
This study has shown a low prevalence of malaria infection
among HIV infected pregnant women using the dailyco-trimoxazole prophylaxis; however, a significant propor-
tion of subjects had anaemia. Good adherence to co-
trimoxazole prophylaxis was associated with reduction of
both malaria infection and anaemia. Routine counselling
and provision of health education on the importance of
good adherence to medications and the consequences of
poor adherence are paramount in addressing the existing
problems. Mitigation of advanced HIV/AIDS among preg-
nant women is also important in combating the problem of
anaemia. Approaches like early diagnosis and timely initi-
ation of anti-retroviral treatment could be of benefit. Due
to the complexity and multiple etiologies of anaemia; other
measures like de-worming, schistosomiasis control and nu-
tritional supplementation should be taken on board.
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